These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 33812801)
1. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801 [TBL] [Abstract][Full Text] [Related]
2. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917 [TBL] [Abstract][Full Text] [Related]
3. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C Cells; 2021 Oct; 10(11):. PubMed ID: 34831159 [TBL] [Abstract][Full Text] [Related]
4. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Xiaobo C; Majidi M; Feng M; Shao R; Wang J; Zhao Y; Baladandayuthapani V; Song J; Fang B; Ji L; Mehran R; Roth JA Sci Rep; 2016 Nov; 6():35741. PubMed ID: 27845352 [TBL] [Abstract][Full Text] [Related]
5. Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth. Johnson SS; Liu D; Ewald JT; Robles-Planells C; Pulliam C; Christensen KA; Bayanbold K; Wels BR; Solst SR; O'Dorisio MS; Menda Y; Spitz DR; Fath MA Cancer Biol Ther; 2024 Dec; 25(1):2382524. PubMed ID: 39054566 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042 [TBL] [Abstract][Full Text] [Related]
7. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. Lai SL; Perng RP; Hwang J J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891 [TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126 [TBL] [Abstract][Full Text] [Related]
9. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53. Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681 [TBL] [Abstract][Full Text] [Related]
10. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Hedström E; Eriksson S; Zawacka-Pankau J; Arnér ES; Selivanova G Cell Cycle; 2009 Nov; 8(21):3584-91. PubMed ID: 19838062 [TBL] [Abstract][Full Text] [Related]
11. Morin enhances auranofin anticancer activity by up-regulation of DR4 and DR5 and modulation of Bcl-2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells. Hwang-Bo H; Lee WS; Nagappan A; Kim HJ; Panchanathan R; Park C; Chang SH; Kim ND; Leem SH; Chang YC; Kwon TK; Cheong JH; Kim GS; Jung JM; Shin SC; Hong SC; Choi YH Phytother Res; 2019 May; 33(5):1384-1393. PubMed ID: 30887612 [TBL] [Abstract][Full Text] [Related]
12. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition. Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178 [TBL] [Abstract][Full Text] [Related]
13. Chloroquine induces transitory attenuation of proliferation of human lung cancer cells through regulation of mutant P53 and YAP. Saini H; Choudhary M; Sharma H; Chowdhury S; Mukherjee S; Chowdhury R Mol Biol Rep; 2023 Feb; 50(2):1045-1058. PubMed ID: 36385665 [TBL] [Abstract][Full Text] [Related]
14. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Li C; Hu J; Li W; Song G; Shen J Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577 [TBL] [Abstract][Full Text] [Related]
15. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment. Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343 [TBL] [Abstract][Full Text] [Related]
16. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells. Kato I; Kasukabe T; Kumakura S Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449 [TBL] [Abstract][Full Text] [Related]
17. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species. Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723 [TBL] [Abstract][Full Text] [Related]
18. NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling. Jin X; Liu X; Zhang Z; Xu L Biochem Biophys Res Commun; 2020 Dec; 533(3):354-361. PubMed ID: 32962856 [TBL] [Abstract][Full Text] [Related]
19. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells. Hu Z; Zeng Q; Zhang B; Liu H; Wang W Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870 [TBL] [Abstract][Full Text] [Related]
20. Daucosterol disturbs redox homeostasis and elicits oxidative-stress mediated apoptosis in A549 cells via targeting thioredoxin reductase by a p53 dependent mechanism. Rajavel T; Banu Priya G; Suryanarayanan V; Singh SK; Pandima Devi K Eur J Pharmacol; 2019 Jul; 855():112-123. PubMed ID: 31059712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]